A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus

American Journal of Transplantation

Volumn 5, Issue 1, 2005, Pages 157-166

  Woodle, E Steve ^a   Vincenti, Flavio ^b   Lorber, Marc I ^c   Gritsch, H Albin ^d   Hricik, Donald ^e   Washburn, Kenneth ^f   Matas, Arthur J ^g   Gallichio, Michael ^h   Neylan, John ⁱ  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

Corticosteroid withdrawal; Kidney transplant; Sirolimus; Steroids

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BASILIXIMAB; CORTICOSTEROID; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CADAVER DONOR; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; BIOPSY; BLOOD PRESSURE; BODY WEIGHT; CADAVER; CARDIOVASCULAR SYSTEM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; RISK FACTORS; SIROLIMUS; STEROIDS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 11844262690     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00655.x     Document Type: Article

References (23)

1. First MR, Munda R, Kant KS, Fidler JP, Alexander JW. Steroid withdrawal following HLA-identical related donor transplantation. Transplant Proc 1981; 13: 319-322.
2. Kupin W, Venkat KK, Oh HK, Dienst S. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 53-55.
3. Flechner SM, Kerman RH, Van Buren CT, Epps L, Kahan BD. The use of cyclosporine in living-related renal transplantation: Donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 1984; 38: 685-691.
4. Boots JM, Christiaans MH, Van Duijnhoven EM, Van Suyle RJ, Van Hoof JP. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: A pilot study. Transplantation 2002; 74: 1703-1709.
5. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234-241.
6. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-A prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874.
7. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1271-1272.
8. Mahalati K, Kahan BD. Sirolimus permits steroid withdrawal from a cyclosporine regimen. Transplant Proc 2001; 33: 1270.
9. McDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003; 35 (3 Suppl): 201S-208S.
10. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factor progression, and prognosis. Transplantation 2003; 76: 375-382.
11. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesch HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046.
12. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689.
13. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
14. Kahan BD, Stepkowski SM, Napoli KL, Katz SM, Knight RJ, Van Buren C. The development of sirolimus: The University of Texas-Houston experience. Clin Transplant 2000; 14: 145-158.
15. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042.
16. Tornatore KM, Biocevich DM, Reed KA et al. Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients. Clin Transplant 1995; 9: 189-196.
17. Tornatore KM, Logue G, Venuto RC, Davis PJ. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol 1997; 37: 304-311.
18. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 937-938.
19. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-440.
20. Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicenter study. Lancet 2000; 356: 194-202.
21. Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus versus mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3; 1128-1134.
22. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2000; 74: 804-808.
23. Rogers CC, Alexander JW, Alloway RR et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy: 2 year followup in 109 patients. Am J Transplant 2004; 4 (Suppl 8): 434.